[Clinical usefulness of FUT-187 (sepimostat mesilate) on reflux esophagitis and gastritis after gastrectomy].
The efficacy and safety of the proteolytic enzyme inhibitor FUT-187 were evaluated in postgastrectomy reflux esophagitis and gastric remnant inflammation. FUT-187 was administered orally in a dose of 50 mg four times daily, after meals and bedtime, for periods of 4 to 8 weeks. The subjects consisted of 4 patients with postgastrectomy reflux esophagitis and 9 patients with gastric remnant inflammation. In the endoscopic classification of lesions, postgastrectomy reflux esophagitis was classified as erosive or ulcerative and gastric remnant inflammation as superficial. The general improvement rating, general improvement rating of endoscopic findings, and final global improvement rating were 85% (11/13), 82% (9/11), and 85% (11/13), respectively. Neither adverse reactions nor abnormal laboratory findings due to the test drug were noted. Based on the results of this study, it may be concluded that FUT-187 is an effective drug with a wide margin of safety for postgastrectomy reflux esophagitis and gastric remnant inflammation.
Makuuchi
H
H
Second Dept. of Surgery, School of Medicine, Tokai University.
Kanno
K
K
Mitomi
T
T
D000284:Administration, Oral; D000368:Aged; D004942:Esophagitis, Peptic / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D005756:Gastritis / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011178:Postgastrectomy Syndromes / Q000188:drug therapy*; D013274:Stomach Neoplasms / Q000601:surgery; D013276:Stomach Ulcer / Q000601:surgery
D007093:Imidazoles; C058875:sepimostate mesilate